Search PubMed⌕ Search

Biomedical subjects

K Whaley

Publications and source records attributed to K Whaley.

At least 199 records · Page 11Linked to original sources

Clinical trial of lincomycin hydrochloride in Reiter's disease.

A double-blind trial comparing lincomycin hydrochloride (Mycivin) and placebo in 22 patients with Reiter's disease showed no significant difference in clinical or laboratory findings between the two groups. It is concluded that lincomycin hydrochloride is no more effective than placebo in the treatment of Reiter's disease.

Adult↗

Comparison of the adrenocorticotrophic activities of two synthetic polypeptides: synacthen and DW 75.

The adrenocorticotrophic activities of two synthetic polypeptides, Synacthen (Ciba) and DW 75 (Sandoz), were compared in two groups of patients having a variety of arthritic disorders. Compared with Synacthen, injected either intramuscularly or intravenously, intravenous DW 75 was found to have a longer duration of adrenocorticotrophic activity (measured by plasma 11-hydroxycorticosteroid levels) in both groups of patients, while intramuscularly administered DW 75 did not appear to be absorbed well.

Adrenal Cortex Hormones↗

Purification and characterization of RHP (factor H) and study of its interactions with the first component of complement.

RHP has been purified from the plasma of both normal individuals and patients with rheumatoid arthritis (RA). RHP from both these sources was shown to be identical with Factor H by reaction with antisera and N-terminal amino acid sequence analysis. Factor H, from both normal and RA sera, inhibited the solubilization of immune precipitates but did not affect prevention of immune precipitation. Factor H was shown to inhibit the haemolytic activity of fluid-phase C1, but unlike C1-inhibitor, it had little effect on C1 bound to EA (EAC1). Factor H was shown to complex with intact C1, to isolated C1q and to the C1r:C1s tetramer. However, binding of factor H to C1 did not dissociate the C1 macromolecule. A C1-Factor H complex was detected in the serum and plasma from normal individuals and patients with systemic lupus erythematosus and RA. Serum levels of this complex were reduced, by EDTA-treatment of serum and by activation of complement by the classical pathway.

Arthritis, Rheumatoid↗